LIR Life Sciences Launches Phase 2 Peptide Design with Neuland to Boost Transdermal Therapies
Phase 2 launch: LIR Life Sciences & Neuland Labs advance peptide‑design for next‑gen transdermal delivery, boosting non‑invasive therapeutics potential.
2 minutes to read